Nanatinostat

Generic Name: Nanatinostat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₀H_₁₉FN_₆O_₂

CAS Number: 1256448-47-1

Unique Ingredient Identifier: YTL7A418KQ

Background: Nanatinostat is under investigation in clinical trial NCT00697879 (Safety Study of the Histone Deacetylase Inhibitor, CHR-3996, in Patients With Advanced Solid Tumours).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Post-Transplant Lymphoproliferative Disorder Drug Pipeline

The 'Post-Transplant Lymphoproliferative Disorder - Pipeline Insight, 2024' report by ResearchAndMarkets.com details 3+ companies and 3+ pipeline drugs for PTLD, covering drug profiles, therapeutic assessment, and inactive products. Key players include Viracta Therapeutics with Nana-Val (Nanatinostat and Valganciclovir), focusing on novel treatments. The report highlights ongoing clinical trials, collaborations, and emerging trends in PTLD therapeutics.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy